Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 2-Visit rabies vaccine schedule offer the same protection as 3?

NCT ID NCT06066294

Prevention Sponsor: Kempegowda Institute of Medical Sciences, Bangalore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether a two-visit rabies vaccine schedule (with two small doses on day 0 and day 7) is as safe and effective as the standard three-visit schedule (with one dose on days 0, 7, and 28) in healthy adults. The goal is to see if both schedules produce a strong immune response and to compare side effects. Participants will receive the rabies vaccine and have blood samples taken to measure antibody levels over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rabies vaccine (Rabivax-S)
What this could lead to
If successful, this could lead to a simpler, shorter rabies vaccination schedule, making pre-exposure protection easier and more accessible.
What could go wrong
The trial is relatively small and results may not apply to everyone. There is also a risk of side effects, such as local reactions or allergic responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

144 people

The number who actually took part.

Started

Apr 2023

Finished

Jan 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy subjects willing to volunteer and sign written informed consent for the study. * Subjects should be available for the follow-up period. Exclusion Criteria: * Received Anti rabies vaccine or RIG or RMAb anytime in the past. * Participation in any other clinical trial in the past three months. * Severely immunocompromised subjects, pregnant and lactating women. * Subjects with known history of allergy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vaccine reaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vaccine reaction

Contacts and locations

Locations

  • Kempegowda Institute Of Medical Sciences Hospital and Research Center

    Bengaluru, Karnataka, 560002, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.